Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering
December 05, 2019 09:25 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...
Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry
December 05, 2019 08:45 ET
|
Akers Biosciences Inc.
· Establishes Advisory Board appointing Bob Hoban and Michael Patterson Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ:...
Akers Biosciences Reports Q1 2019 Earnings
May 20, 2019 17:38 ET
|
Akers Biosciences Inc.
Continued Progress Toward Positioning the Company for Strategic Alternatives THOROFARE, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the...
Akers Biosciences Reports Fiscal Year 2018 Earnings
April 01, 2019 17:31 ET
|
Akers Biosciences Inc.
Ongoing Measures to Streamline Operations, Reduce Costs and Position the Company for Strategic Alternatives THOROFARE, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc....
Akers Biosciences Exploring Potential Business Combinations in Alternative Sectors Including Cannabis Industry
November 19, 2018 09:01 ET
|
Akers Biosciences Inc.
THOROFARE, N.J., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, is...
Akers Biosciences Announces Q3 2018 Earnings
November 15, 2018 07:00 ET
|
Akers Biosciences Inc.
Sales of Flagship PIFA Heparin PF/4 Rapid Assay Products Up 16% over Q3 2017; Company Continuing to Evaluate Strategic Alternatives to Maximize Shareholder Value THOROFARE, N.J., Nov. 15, 2018 ...
Akers Biosciences Announces Intention to Explore Strategic Alternatives to Maximize Shareholder Value
November 07, 2018 09:15 ET
|
Akers Biosciences Inc
Announces 1:8 Reverse Stock Split THOROFARE, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid...
Akers Biosciences to Present at Disruptive Growth & Healthcare Conference
February 08, 2016 12:18 ET
|
Akers Biosciences Inc.
THOROFARE, N.J., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), (“Akers Bio” or the "Company"), a developer of cutting edge technologies that deliver rapid...
Akers Biosciences Appoints Medical Technology Specialist as CEO
November 23, 2015 07:00 ET
|
Akers Biosciences Inc.
THOROFARE, N.J., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of...
Akers Biosciences Announces Q3 2015 Earnings
November 13, 2015 07:00 ET
|
Akers Biosciences Inc.
Flagship Rapid HIT Test Set to be in 250 US Hospitals by Year End
Conference Call Scheduled for 9:00 a.m. EST Today
THOROFARE, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc....